GlassScriptPhysician profile
Britt A Stroud
NPI 1336368927
$10,726.21
in general payments reported to CMS, 2019-2025
30 companies · $8,748 in 2025
The $8,748 reported for 2025 was more than what 89% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $246 · 2021: $120 · 2022: $61.83 · 2023: $279 · 2024: $155 · 2025: $8,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,900 · Food and Beverage: $1,319 · Travel and Lodging: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,900.00 |
| Food and Beverage | $1,319.32 |
| Travel and Lodging | $963.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,117.32 | 2019-2025 | |
| Livanova USA, INC. | $324.97 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $304.80 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $274.77 | 2019-2020 | |
| Ucb, INC. | $230.43 | 2019-2025 | Fintepla, Briviact |
| Eisai INC. | $144.79 | 2019 | |
| Genentech USA, INC. | $137.99 | 2023-2025 | Evrysdi |
| Tris Pharma INC | $124.49 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $123.45 | 2023 | Aptiom |
| Genentech, INC. | $114.02 | 2024 | Evrysdi |
| Corium, LLC | $89.92 | 2021-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $87.45 | 2019-2025 | |
| Otter Pharmaceuticals, LLC | $86.24 | 2025 | Sympazan |
| Neurelis, INC. | $84.55 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $66.56 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $59.69 | 2019-2020 | |
| Aucta Pharmaceuticals, INC. | $53.64 | 2025 | Motpoly Xr |
| Supernus Pharmaceuticals, INC. | $50.09 | 2019 | |
| Collegium Pharmaceutical, INC. | $42.29 | 2025 | Jornay Pm |
| Allergan, INC. | $26.36 | 2019 | |
| Nobelpharma America, LLC | $25.00 | 2024 | |
| Acadia Pharmaceuticals INC | $24.89 | 2025 | Daybue |
| Sarepta Therapeutics, INC. | $22.56 | 2025 | Elevidys |
| Aquestive Therapeutics, INC. | $18.66 | 2019 | |
| Springworks Therapeutics, INC. | $18.13 | 2025 | Gomekli |
| Zogenix INC. | $16.68 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $16.45 | 2019 | |
| Saol Therapeutics INC. | $14.34 | 2019 | |
| Travere Therapeutics, INC. | $13.50 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britt Stroud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.